Market Overview

Vetr Crowd Upgrades Bluebird After Trump Presser


On Wednesday, the Vetr crowd upgraded their rating for bluebird bio Inc (NASDAQ: BLUE), from 2.5 Stars (Sell) issued two days ago, to 3.5 Stars (Buy). Crowd sentiment for the stock is generally cautious, with 66 percent of Vetr user ratings bearish.

The gene therapy company experienced the same drop many biotech firms experienced in the wake of President-elect Donald Trump's first press conference following his election win in November. The sector saw an immediate selloff following the President-elect's comment about the cost of consumer drug prices.

Shares of bluebird bio fell over 5 percent to $64.70 immediately following the remark made around noon on January 11. The stock bounced back slightly as traders capitalized on the market's reaction. The stock still finished the day down at $65.05.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for the stock is up at $69.48, which is well below the average analyst target price of $88.77. Less than 2 percent of Vetr users are holding BLUE in their watch lists.

Latest Ratings for BLUE

Dec 2019UpgradesPerformOutperform
Dec 2019MaintainsOverweight
Nov 2019UpgradesMarket PerformOutperform

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Crowdsourcing Analyst Ratings


Related Articles (BLUE)

View Comments and Join the Discussion!

Latest Ratings

RPAYCantor FitzgeraldMaintains18.0
CMSCredit SuisseDowngrades
PBCTStephens & Co.Maintains15.5
TTECCowen & Co.Initiates Coverage On50.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at